- Home
- Equipment
- usa massachusetts
- preclinical modeling
Show results for
Refine by
Preclinical Modeling Equipment Supplied In Usa Massachusetts
17 equipment items found
by:Sumitomo Pharma Oncology, Inc. based inCambridge, MASSACHUSETTS (USA)
TP-1287 is an investigational oral CDK9 inhibitor that has shown favorable oral bioavailability in preclinical models. TP-1287 is enzymatically cleaved, yielding the active moiety, a potent inhibitor of CDK9.35 Inhibiting CDK9 is thought to downregulate the transcription of target genes, including MCL-1, reducing leukemic blast viability in MCL-1–dependent ...
Manufactured by:AVEO Pharmaceuticals, Inc. based inBoston, MASSACHUSETTS (USA)
FOTIVDA was approved in August 2017 in the European Union and other countries in the territory of its partner EUSA Pharma for the treatment of adult patients with advanced RCC. Tivozanib has been shown to significantly reduce regulatory T-cell production in preclinical models.3 Tivozanib was discovered by Kyowa Kirin (KKC) and is also being studied as a new ...
Manufactured by:Adiso Therapeutics based inConcord, MASSACHUSETTS (USA)
ADS00X has demonstrated pre-clinical efficacy in 3 models of neuroinflammatory disease. Adiso is pursuing confirmatory evidence which supports the impact of our SS-LBP products on the Gut-Brain Axis. ...
by:Sumitomo Pharma Oncology, Inc. based inCambridge, MASSACHUSETTS (USA)
TP-0184 is an investigational inhibitor of activin receptor-like kinase 2 (ALK2) and ALK5 (also known as TGFβR1). This bimodal inhibitor is believed to downregulate multiple TGF-β superfamily signaling pathways and has shown antitumor activity in several ...
Manufactured by:Suono Bio based inFoxborough, MASSACHUSETTS (USA)
We have reimagined ultrasound as a simple and effective delivery platform, which acts on the therapeutic molecules themselves, achieving ultra-rapid, formulation-independent drug delivery. This enables us to “push” virtually any therapeutic class, including temperamental molecules, like nucleic acids, directly into cells with astounding efficacy and accuracy, affecting historically ...
by:Myeloid Therapeutics based inCambridge, MASSACHUSETTS (USA)
MT-303 represents the first candidate in a new therapeutic modality targeting hepatocellular carcinoma (HCC). Liver cancer is a prevalent and challenging cancer with over 850,000 new cases diagnosed globally each year, and the third leading cause of cancer death. The clinical candidate is a first-in-class, GPC3-FcA-LNP, with a strong preclinical profile supporting its advance into this ...
Manufactured by:Mersana Therapeutics based inCambridge, MASSACHUSETTS (USA)
Once ADCs release their cytotoxic payload into targeted cells, the drug is often able to cross cell membranes, entering and potentially killing neighboring cells whether those cells are cancerous or not. This effect is called bystander-killing, which is advantageous when bystander cells are cancerous but toxic if the cytotoxic drug is able to enter adjacent healthy cells. The DolaLock payload ...
Manufactured by:TargetMol Chemicals Inc. based inWellesley Hills, MASSACHUSETTS (USA)
A stable and high affinity triple complex is formed between RMC-9805, KRASG12D, and cyclophilin A, which inhibits signal transduction downstream of KRASG12D (ON) by disrupting its interaction with downstream effectors. RMC-9805 can induce cell apoptosis and promote tumor regression in preclinical KRASG12D tumor models. With rich experience in compound synthesis, ...
Manufactured by:MorphoSys AG based inPlanegg, GERMANY
Tulmimetostat is a second-generation EZH2 inhibitor that has been designed to achieve comprehensive target coverage through extended on-target residence time. EZH2 acts as an epigenetic writer and normally places one or more methyl groups on a histone protein, leading to the suppression of gene expression. Some cancers depend on an abnormal pattern of gene expression and re-direct EZH2 to genes ...
by:Sumitomo Pharma Oncology, Inc. based inCambridge, MASSACHUSETTS (USA)
Dubermatinib (TP-0903) is an investigational inhibitor of AXL receptor tyrosine kinase (RTK), a protein known to be involved in acquiring resistance to chemotherapeutics, immune evasion, and developing metastatic capacity in cancer ...
by:Sumitomo Pharma Oncology, Inc. based inCambridge, MASSACHUSETTS (USA)
DSP-0509 is an investigational Toll-like receptor (TLR) 7 agonist, which is hypothesized to induce cytokine production, activate cytotoxic T lymphocytes, and sustain immune-mediated antitumor ...
by:Sumitomo Pharma Oncology, Inc. based inCambridge, MASSACHUSETTS (USA)
TP-1454 is an investigational oral pyruvate kinase M2 isoform (PKM2) activator.44 This activation is thought to starve cancer cells of important molecular building blocks, inhibiting tumor cell proliferation, and enhancing antitumor ...
Manufactured by:Emulate based inBoston, MASSACHUSETTS (USA)
Study drug absorption and drug-drug interactions in a primary organoid-based model of the human small ...
Manufactured by:Emulate based inBoston, MASSACHUSETTS (USA)
Investigate mechanisms of toxicity for preclinical drug candidates to help decrease clinical trial safety failures. Drug-induced liver injury (DILI) is a primary concern during drug development that remains poorly understood due to species differences in liver toxicity and the limited predictivity of conventional in vitro models. ...
Manufactured by:Emulate based inBoston, MASSACHUSETTS (USA)
Investigate mechanisms of colon inflammation and barrier disruption and evaluate the efficacy of anti-inflammatory drug candidates in an organoid-derived ...
Manufactured by:CervoMed based inBoston, MASSACHUSETTS (USA)
Our lead product candidate, Trans sodium crocetinate (TSC), is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine’s most intractable and difficult-to-treat conditions. ...
Manufactured by:Inovotion Sas based inLa Tronche, FRANCE
INOVOTION has developed a unique, highly sensitive and reproducible assay. It is applicable to all preclinical oncology and immuno-oncology drug discovery programs, and monitors the growth and metastatic dissemination of human tumor ...